NKTR-214 has been shown to improve antitumor immunity in mouse cancer models, including the B16-F10 melanoma and the CT26 colon carcinoma when combined with the gp100 self TAA or the endogenous retroviral AH-1 TAA vaccine, respectively (113, 114). The gene discussed is PMEL; the disease is melanoma.